ZOPDULAG Trademark

Trademark Overview

On Wednesday, April 29, 2020, a trademark application was filed for ZOPDULAG with the United States Patent and Trademark Office. The USPTO has given the ZOPDULAG trademark a serial number of 88894029. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 2, 2024. This trademark is owned by Bristol-Myers Squibb Company. The ZOPDULAG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use
zopdulag

General Information

Serial Number88894029
Word MarkZOPDULAG
Filing DateWednesday, April 29, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 31, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 12, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Saturday, May 2, 2020NEW APPLICATION ENTERED
Tuesday, May 12, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 23, 2020ASSIGNED TO EXAMINER
Thursday, July 30, 2020NON-FINAL ACTION WRITTEN
Thursday, July 30, 2020NON-FINAL ACTION E-MAILED
Thursday, July 30, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 25, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 25, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 26, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 28, 2021FINAL REFUSAL WRITTEN
Thursday, January 28, 2021FINAL REFUSAL E-MAILED
Thursday, January 28, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, July 23, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, July 23, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 23, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 27, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 11, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 31, 2021PUBLISHED FOR OPPOSITION
Tuesday, August 31, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 26, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, April 8, 2022SOU TEAS EXTENSION RECEIVED
Friday, April 8, 2022SOU EXTENSION 1 FILED
Friday, April 8, 2022SOU EXTENSION 1 GRANTED
Tuesday, April 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 6, 2022SOU TEAS EXTENSION RECEIVED
Thursday, October 6, 2022SOU EXTENSION 2 FILED
Thursday, October 6, 2022SOU EXTENSION 2 GRANTED
Saturday, October 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 6, 2023SOU TEAS EXTENSION RECEIVED
Thursday, April 6, 2023SOU EXTENSION 3 FILED
Thursday, April 6, 2023SOU EXTENSION 3 GRANTED
Saturday, April 8, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, October 11, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 11, 2023SOU EXTENSION 4 FILED
Wednesday, October 11, 2023SOU EXTENSION 4 GRANTED
Thursday, March 14, 2024SOU EXTENSION 5 GRANTED
Friday, October 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 14, 2024SOU TEAS EXTENSION RECEIVED
Thursday, March 14, 2024SOU EXTENSION 5 FILED
Friday, March 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

zopdulag diseases pharmaceutical human preparations disorders cancer immune namely anti system